| Literature DB >> 25371714 |
Fangju Su1, Weize Zhang1, Yongqing Chen1, Ling Ma1, Hanping Zhang1, Fei Wang1.
Abstract
Atrial interstitial fibrosis plays a dual role in inducing and maintaining atrial fibrillation (AF). Hypoxia-inducible factor-1α (HIF-1α) has been reported as closely associated with renal, liver and pulmonary fibrosis diseases. However, whether HIF-1α is involved in myocardial fibrosis, and the associations between HIF-1α, transforming growth factor-β1 (TGF-β1) and matrix metalloproteinase-9 (MMP-9) remain unknown. Therefore, this area warrants studying for the significance of AF diagnosis and treatment. The present study investigated the expression of HIF-1α in atrial fibrosis and its possible mechanism in isoproterenol (ISO)-induced rats. The three groups of rats; control, ISO and ISO plus sirolimus [also known as rapamycin (Rapa)], were treated for 15 days and sacrificed to remove the myocardial tissues. The expression levels of HIF-1α, TGF-β1 and MMP-9 and their associations with atrial fibrosis were examined through histomorphology and protein and mRNA levels. The protein and mRNA levels of HIF-1α, TGF-β1 and MMP-9 in the ISO group were increased markedly (P<0.01) compared with the control group, while those in the Rapa group were clearly decreased (P<0.01) compared with the ISO group. The protein and mRNA levels of HIF-1α, TGF-β1 and MMP-9 were positively correlated (P<0.01) with atrial fibrosis (collagen volume fraction index), as were the HIF-1α, TGF-β1 and MMP-9 mRNA levels (P<0.01) and the mRNA levels between MMP-9 and TGF-β1 (P<0.01). During the process of atrial fibrosis in ISO-induced rats, HIF-1α promotes the expression of TGF-β1 and MMP-9 protein, and thus is involved in in atrial fibrosis.Entities:
Keywords: atrial; fibrosis; hypoxia inducible factor-1α; matrix metalloproteinase-9; transforming growth factor-β1
Year: 2014 PMID: 25371714 PMCID: PMC4218706 DOI: 10.3892/etm.2014.1989
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1Myocardial interstitial fibrosis performance. (A–C) Hematoxylin and eosin staining; (D–F) Masson staining (green represents the myocardial interstitial collagen component). (A and D) Control; (B and E) ISO; and (C and F) Rapa groups (magnification, ×400). ISO, isoproterenol; Rapa, ISO plus sirolimus.
Figure 2Immunohistochemistry results of HIF-1α, TGF-β1 and MMP-9 expression. Comparison of HIF-1α, TGF-β1 and MMP-9 expression in myocardial cells (claybank spots) in the cytoplasm represents positive staining. (A, D and G) Control; (B, E and H) ISO; and (C, F and I) Rapa groups (magnification, ×400). ISO, isoproterenol; Rapa, ISO plus sirolimus; HIF-1α, hypoxia-inducible factor-1α; TGF-β1, transforming growth factor-β1; MMP-9, matrix metalloproteinase-9.
Western blot analysis and RT-qPCR results of HIF-1α, TGF-β1 and MMP-9.
| HIF-1α | TGF-β1 | MMP-9 | ||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Group | Protein | mRNA | Protein | mRNA | Protein | mRNA |
| Control | 0.294±0.021 | (5.795±0.822)×10−5 | 0.660±0.059 | (1.223±0.085)×10−2 | 0.974±0.116 | (2.596±0.193)×10−6 |
| ISO | 0.522±0.039 | (2.103±0.492)×10−4 | 1.444±0.081 | (7.511±0.156)×10−2 | 1.939±0.113 | (4.854±0.210)×10−6 |
| Rapa | 0.279±0.016 | (6.374±0.993)×10−5 | 0.669±0.040 | (1.205±0.090)×10−2 | 0.916±0.125 | (2.789±0.180)×10−6 |
P<0.01 compared with the control group;
P<0.01 compared with the ISO group.
RT-qPCR, reverse transcription quantitative polymerase chain reaction; ISO, isoproterenol; Rapa, ISO plus sirolimus; HIF-1α, hypoxia-inducible factor-1α; TGF-β1, transforming growth factor-β1; MMP-9, matrix metalloproteinase-9.
Figure 3Protein expression of HIF-1α, TGF-β1 and MMP-9. **P<0.01 compared with the control group, ##P<0.01 compared with the ISO group. ISO, isoproterenol; Rapa, ISO plus sirolimus; HIF-1α, hypoxia-inducible factor-1α; TGF-β1, transforming growth factor-β1; MMP-9, matrix metalloproteinase-9.